UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect
Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential.
Arcellx Inc. (ACLX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,036,527 | $249,298,867 | 3.07% | |
| 2. | Perceptive Advisors Joseph Edelman | 2,468,353 | $202,651,781 | -1% | 5.85% |
| 3. | SR One Capital Simeon George | 2,346,630 | $192,658,323 | 27.86% | |
| 4. | Vestal Point Capital Ryan Wilder | 1,250,000 | $102,625,000 | -55% | 4.63% |
| 5. | Citadel Investment Group Ken Griffin | 1,021,453 | $83,861,291 | +415% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 312,500 | $5,000,000.00 | 6,745,262 | 2022-06-21 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing | |
| $15.00 | 66,667 | $1,000,005.00 | 3,466,811 | 2022-02-08 | Filing | |
| $15.00 | 1,583,333 | $23,749,995.00 | 6,432,762 | 2022-02-08 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.00 | 6,000 | $450,000.00 | 21,659 | 2026-01-20 | Filing | |
| $68.51 | 5,882 | $402,997.00 | 23,749 | 2026-01-14 | Filing | |
| $65.51 | 7,437 | $487,212.74 | 29,631 | 2026-01-13 | Filing | |
| $64.15 | 6,131 | $393,285.87 | 37,068 | 2026-01-12 | Filing | |
| $90.00 | 340 | $30,600.00 | 284 | 2025-11-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,081,519 | $266,115,040 | 0% | |
| 2. | 342,612 | $22,338,302 | 0.02% | |
| 3. | 316,612 | $20,643,103 | 0% | |
| 4. | 60,364 | $3,935,733 | 0.01% | |
| 5. | 59,063 | $3,850,908 | 0.61% |
News See All
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
On November 25, 2025, Arcellx, Inc. (NASDAQ:ACLX) saw Morgan Stanley’s Judah Frommer reiterate a “Buy” rating.
12 Oversold Global Stocks to Invest In
Appearing in an interview with CNBC on November 21, 2025, David Katz of Matrix Asset Advisors called widespread weakness a potential entry point, saying that the current correction is “much closer to...
11 Best Cancer Stocks to Buy Right Now
Cancer remains the second leading cause of death globally, after heart disease.
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Here’s Why Arcellx (ACLX) Declined in Q1
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
